Full TitleATLAS: A Phase 2, Open-label Study of Rucaparib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
Advanced or metastatic urothelial cancers of the bladder and urinary tract are commonly treated with chemotherapy and/or immunotherapy. However, there are no approved therapies if the cancers grow despite these therapies.
Rucaparib is a therapy which blocks the activity of PARP. PARP is a protein that helps cells, including cancer cells, repair their damaged DNA. Some cancer cells, including urothelial cancers, may have certain genetic mutations which lead to a reduced ability to repair this damage, and they therefore rely on the PARP protein to repair their DNA and survive. If the PARP protein is blocked, these cells may die.
In this study, researchers are evaluating rucaparib to treat inoperable or metastatic urothelial cancer (including bladder cancer) that has continued to grow despite chemotherapy or immunotherapy. Rucaparib is taken orally (by mouth).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have inoperable or metastatic urothelial cancer (such as renal pelvis, ureter, urinary bladder, or urethra cancer) that has continued to grow despite one or two prior regimens of therapy which included platinum-based chemotherapy or immunotherapy.
- Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
- This study is for patients age 18 and older.
For more information and to inquire about eligibility for this study, please contact Dr. Min Yuen Teo at 646-888-4867.